Environmental, Social and Governance (ESG) factors

UNION’s ESG ambition and ESG focus areas take departure in the company’s patient-centric vision around development of medicines that make a difference by improving the lives of patients with immunological and infectious diseases.

From the headquarters in Hellerup, Denmark, UNION’s dedicated employees work with patient organizations, physicians, investigators, regulatory authorities, and external suppliers, including clinical research organizations and contract development and manufacturing organizations, among other key stakeholders, to progress the current product candidates orismilast and niclosamide throughout the pipeline and into the hands of patients, improving their health and well-being

Environmental responsibility – Achieving carbon neutrality and engaging with suppliers

Due to the business model of UNION where many activities are outsourced, including manufacturing, distribution and clinical study execution, UNION’s direct impact on the environment and climate is minimal. However, UNION wants to contribute to the UN Sustainable Development Goal on Climate Action and acknowledges that indirect CO2 emissions across the value chain are what matter for a company like UNION. In order to create more transparency on emissions across the value chain, UNION has in 2021 partnered with a global leader in science-based carbon accounting to estimate and track the company’s carbon footprint across Scope 1 (direct emissions from vehicle and fuel use), Scope 2 (indirect emissions from electricity and heating) and Scope 3 (indirect emissions from purchased goods and services, transportation and business travel).

Total emissions: 4,080 ton CO2

UNION’s carbon footprint in 2021

UNION is estimating the company’s carbon footprint on an annual basis going forward. Based on the carbon footprint of 2022, UNION will invest in carbon removal technology and/or advanced nature-based solutions, offsetting scope 2 emissions to achieve carbon neutrality across scope 1 and scope 2. With respect to scope 3, UNION is engaging with key suppliers, for example suppliers responsible of development of drug substance, development of drug product, packaging and labelling, pre-clinical toxicology studies as well as clinical study execution, to improve transparency of UNION’s indirect emissions and identify specific CO2-minimizing initiatives.

Social responsibility – Making a difference for patients and fostering a meaningful company culture among employees

UNION is a pharmaceutical development company with core expertise in identification of unmet medical needs, pharmaceutical innovation and clinical development. Please refer to the pages on Psoriasis, Atopic dermatitis and Hidradenitis suppurativa to read more about the unmet medical needs in the disease areas within immuno-dermatology that UNION is initially targeting with orismilast and refer to the page on COVID-19 to read more about the unmet medical need among immunocompromised patients that UNION is focusing on with niclosamide.  


The UNION Way – Company Culture

Passionately creating medicines that make a difference entails passionate employees

Attracting and retaining passionate employees require a good and healthy working environment but also a robust company culture centered around strong virtues and winning behaviors. UNION is tracking the meaningfulness of employees with respect to purpose, leadership, belonging and personal growth in employee surveys twice a year and based on the survey results running initiatives and workshops on an ongoing basis to strengthen The UNION Way and work with the virtues in practice. 

Read more about The UNION Way here.

Corporate governance – Building a lasting pharmaceutical company based on strong ethics and transparency

The organization at UNION has strengthened significantly over the last few years with hiring of personnel and addition of key competencies across all layers, including Board of Directors, Management and the broader team. The organization has not only strengthened in terms of people but also with respect to policies, processes and guidelines, compliance and risk management.

As a company developing treatments to improve and save lives, it is important that all people related to UNION’s business are treated with respect and dignity. This includes respecting human rights, respecting privacy of personal data, welcoming diversity, respecting the freedom of association and collective bargaining, and opposing child labor as well as forced labor and human trafficking. Business ethics and ESG factors are being integrated in UNION’s policy framework, including Sustainability Policy, Code of Conduct as well as Diversity Policy.

UNION is developing a structured non-financial reporting framework to track and report, both internally and externally, on relevant ESG metrics to evaluate the company’s progress on a continuous basis.